A U.S. patent has been issued to Immunomedics, Inc. for epratuzumab, a monoclonal antibody under development as a potential new treatment for lupus. In August of 2009, Immunomedics and its partner, UCB of Belgium, reported promising data from a phase IIb clinical study of epratuzumab involving 227 individuals with moderate to severe lupus. Learn more about these results...

More...